<DOC>
	<DOCNO>NCT00052039</DOCNO>
	<brief_summary>Study GIPF-003 Phase 3b study design define well therapeutic use IFN-gamma 1b patient wtih IPF . The study conduct primarily Europe enroll 210 patient .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Three-Arm , Phase 3b Study Comparing Safety Efficacy Interferon Gamma-1b With Azathioprine , Azathioprine Alone Patients With IPF Receiving Prednisone</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>idiopathic pulmonary fibrosis</keyword>
</DOC>